This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greenblatt, D. Y. Articles by Chen, H. Search for Related Content PubMed PubMed Citation Articles by Greenblatt, D. Y. Articles by Chen, H.

Endocrinology

Valproic Acid Activates Notch-1 Signaling and Regulates the Neuroendocrine Phenotype in Carcinoid Cancer Cells

Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin, and the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA

Key Words. Valproic acid • Carcinoid tumors • Neuroendocrine tumors • Notch-1 Achaete-scute complex-like 1 (ASCL-1)

Correspondence: Herbert Chen, M.D., F.A.C.S., H4/750 Clinical Science Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA. Telephone: 608-263-1387; Fax: 608-263-7652; e-mail: chen{at}surgery.wisc.edu; kunni{at}surgery.wisc.edu

Received April 24, 2007; accepted for publication May 17, 2007.

Carcinoid tumors are neuroendocrine malignancies that frequently metastasize and secrete hormones that cause debilitating symptoms in patients. In this study we report the effects of valproic acid (VPA), a drug long used for the treatment of epilepsy, on the growth and neuroendocrine phenotype of human carcinoid cancer cells. VPA treatment of gastrointestinal and pulmonary carcinoid cells resulted in a dose-dependent inhibition of cancer cell growth. Western blot analysis revealed degradation of cyclin D1 and an increase in cyclin-dependent kinases p21 and p27 with VPA treatment. Flow cytometry confirmed that the mechanism of VPA-induced growth inhibition is G₁ phase cell cycle arrest. Furthermore, VPA suppressed expression of the neuroendocrine tumor marker chromogranin A. In addition to these effects, VPA also increased levels of full-length Notch-1 and the active Notch-1 intracellular domain. Luciferase reporter assays incorporating the centromere-binding factor 1 (CBF-1) binding site and the achaete-scute complex-like 1 (ASCL-1) promoter confirmed the functional activity of VPA-induced Notch-1. Transfection of Notch-1 small-interfering RNA into carcinoid tumor cells blocked the effects of VPA on Notch-1 activation, ASCL-1 suppression, p21 induction, and cell growth inhibition. VPA also suppressed growth of carcinoid tumors in vivo in a mouse tumor xenograft experiment. These findings confirm the important role of Notch-1 in regulating the growth and neuroendocrine phenotype of carcinoid tumor cells. On the basis of this study, a clinical trial of VPA for patients with advanced carcinoid cancer will be conducted.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				M. R. Cook, S. N. Pinchot, R. Jaskula-Sztul, J. Luo, M. Kunnimalaiyaan, and H. Chen Identification of a Novel Raf-1 Pathway Activator that Inhibits Gastrointestinal Carcinoid Cell Growth Mol. Cancer Ther., February 1, 2010; 9(2): 429 - 437. [Abstract] [Full Text] [PDF]

				V. Poulaki, C. S. Mitsiades, V. Kotoula, J. Negri, C. McMullan, J. W. Miller, P. A. Marks, and N. Mitsiades Molecular Sequelae of Histone Deacetylase Inhibition in Human Retinoblastoma Cell Lines: Clinical Implications Invest. Ophthalmol. Vis. Sci., September 1, 2009; 50(9): 4072 - 4079. [Abstract] [Full Text] [PDF]

				J. T. Adler, M. Cook, Y. Luo, S. C. Pitt, J. Ju, W. Li, B. Shen, M. Kunnimalaiyaan, and H. Chen Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3{beta} Mol. Cancer Ther., April 1, 2009; 8(4): 914 - 920. [Abstract] [Full Text] [PDF]

				Y.-C. Wang, E. Gallego-Arteche, G. Iezza, X. Yuan, M. R Matli, S.-P. Choo, M. B Zuraek, R. Gogia, F. C Lynn, M. S German, et al. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors Endocr. Relat. Cancer, March 1, 2009; 16(1): 267 - 279. [Abstract] [Full Text] [PDF]

				X. Xiao, L. Ning, and H. Chen Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors Mol. Cancer Ther., February 1, 2009; 8(2): 350 - 356. [Abstract] [Full Text] [PDF]

				R. D. Meng, C. C. Shelton, Y.-M. Li, L.-X. Qin, D. Notterman, P. B. Paty, and G. K. Schwartz {gamma}-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity Cancer Res., January 15, 2009; 69(2): 573 - 582. [Abstract] [Full Text] [PDF]

				C. D. Peacock and D. N. Watkins Cancer Stem Cells and the Ontogeny of Lung Cancer J. Clin. Oncol., June 10, 2008; 26(17): 2883 - 2889. [Abstract] [Full Text] [PDF]

				L. Ning, D. Y. Greenblatt, M. Kunnimalaiyaan, and H. Chen Suberoyl Bis-Hydroxamic Acid Activates Notch-1 Signaling and Induces Apoptosis in Medullary Thyroid Carcinoma Cells Oncologist, February 1, 2008; 13(2): 98 - 104. [Abstract] [Full Text] [PDF]